Contineum Therapeutics, Inc. (CTNM)
Nasdaq: CTNM · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2023
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Mar 5, 2026 | Mar 6, 2025 | · | · |
| Revenue | · | 0 | 50,000 | · |
| Research and development | 51,522 | 38,422 | 27,603 | · |
| General and administrative | 16,537 | 12,472 | 6,320 | · |
| Total operating expenses | 68,059 | 50,894 | 33,923 | · |
| Operating income | -68,059 | -50,894 | 16,077 | · |
| Interest expense | · | 0 | 208 | · |
| Interest and investment income | 8,246 | 8,905 | 4,606 | · |
| Other income (expense), net | -165 | -163 | -177 | · |
| Total non-operating income (expense) | 8,081 | 8,636 | 7,093 | · |
| Income before income taxes | -60,143 | -42,258 | 23,170 | · |
| Income tax expense | 0 | 0 | 450 | · |
| Net income | -59,978 | -42,258 | 22,720 | · |
| Net income to common shareholders | · | -42,258 | 3,146 | · |
| Earnings per share, basic | -2.17 | -2.18 | 1.36 | · |
| Earnings per share, diluted | -2.17 | -2.18 | 0.08 | · |
| Weighted average shares, basic | 27,700,855 | 19,352,859 | 2,308,972 | · |
| Weighted average shares, diluted | 27,700,855 | 19,352,859 | 3,395,514 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding